• AstraZeneca Competes Viela Divestment americanpharmaceuticalreview
    March 18, 2021
    AstraZeneca has completed the divestment of its 26.7% ownership in Viela Bio, as part of the proposed acquisition of Viela by Horizon Therapeutics. This follows the agreement to divest the shareholding on February 1, 2021.
  • AstraZeneca to Divest Viela Shareholding americanpharmaceuticalreview
    February 02, 2021
    AstraZeneca has agreed, subject to certain limited exceptions, to divest its 26.7% ownership in Viela Bio, as part of the proposed acquisition of Viela by Horizon Therapeutics.
PharmaSources Customer Service